NEW YORK – The number of mergers and acquisitions in the molecular diagnostics and omics life science tools space rose 13 percent in 2019, continuing the 12 percent climb from the previous year and putting the 4 percent decline the industry saw in 2017 firmly in the rear-view mirror.
According to an analysis by GenomeWeb, there were 62 deals completed in the MDx/omics tools space in 2019 compared to 55 deals in 2018.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
